Story perspectives

FDA Approves Avlayah: First Hunter Syndrome Treatment in 20 Years

4/1/2026

Summary

Story summary

The U.S. Food and Drug Administration approved Avlayah, the first new treatment for Hunter syndrome in 20 years, developed by Denali Therapeutics.
Avlayah is an enzyme replacement therapy intended to halt cognitive decline and extend life expectancy for children with Hunter syndrome.
The approval gives families hope that early treatment could prevent symptoms, but it does not reverse existing damage.
Denali Therapeutics is pursuing insurance coverage and plans to expand research for young adults.
The approval is a significant milestone for the rare disease community, which has faced challenges in securing treatment options.

1 of 1

Story summary

The U.S. Food and Drug Administration approved Avlayah, the first new treatment for Hunter syndrome in 20 years, developed by Denali Therapeutics.
Avlayah is an enzyme replacement therapy intended to halt cognitive decline and extend life expectancy for children with Hunter syndrome.
The approval gives families hope that early treatment could prevent symptoms, but it does not reverse existing damage.
Denali Therapeutics is pursuing insurance coverage and plans to expand research for young adults.
The approval is a significant milestone for the rare disease community, which has faced challenges in securing treatment options.